Investment
Features
FeesSafety
Academy
More
Pluang+

Compare MDU Resources Group Inc. Common Stock (Holding Company) (MDU) vs Relay Therapeutics Inc. Common Stock (RLAY) Price & Performance

MDU Resources Group Inc. Common Stock (Holding Company)Trade
Relay Therapeutics Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

MDU Resources Group Inc. Common Stock (Holding Company) vs Relay Therapeutics Inc. Common Stock — how do they compare? MDU Resources Group Inc. Common Stock (Holding Company) trades at $18.56 (market cap $3.92B), while Relay Therapeutics Inc. Common Stock trades at $17.07 (market cap $3.81B). The key difference: MDU Resources Group Inc. Common Stock (Holding Company) and Relay Therapeutics Inc. Common Stock are close in size by market cap, and MDU Resources Group Inc. Common Stock (Holding Company) pays a 3.03% dividend while Relay Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold MDU Resources Group Inc. Common Stock (Holding Company) for 0 Days and Relay Therapeutics Inc. Common Stock for 5 Days on average.

MDURLAY
Market Cap
$3.92B$3.81B
Volume
1,027,6561,706,150
Sector
UtilitiesHealth
52-Week High
$22.80$20.75
52-Week Low
$18.39$6.05
Typical Hold Time
0 Days5 Days
Enterprise Value
$6.45B$2.93B
Dividend Yield
3.03%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

MDU Resources Group Inc. Common Stock (Holding Company)

No Aura AI signal available yet.

Relay Therapeutics Inc. Common Stock

Relay Therapeutics (RLAY) trades at $17.36, down 3.45% today, with technical indicators showing bearish momentum. The company remains in clinical-stage development with negative profitability metrics, including a -2,763.64% net income margin and -$276.48M net loss for 2025. Recent Q2 2026 earnings missed expectations with a loss of $0.41 per share, though the company continues advancing its oncology pipeline with Phase 3 trials planned for 2027.

Despite unanimous analyst buy ratings and a $26.25 consensus price target representing 51% upside, RLAY faces significant execution risk as a pre-revenue biotech. The stock's bearish technical setup and persistent cash burn require careful risk management, though institutional accumulation and AI-driven drug discovery platform provide long-term potential.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MDU
100% Buy0% Sell
Avg holding period · 0 Days
RLAY

No sentiment data available yet.

About MDU Resources Group Inc. Common Stock (Holding Company)

MDU Resources Group, Inc. is a US holding company operating regulated electric and natural gas utility services alongside a construction materials and services business supplying asphalt, concrete, and aggregates.

Read more on MDU →

About Relay Therapeutics Inc. Common Stock

Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.

Read more on RLAY →